The Mechanism of Action of IVIg in Inflammatory Neuropathy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/571318

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Intravenous immunoglobulin (IVIg) is the major therapy used for the inflammatory neuropathies GBS, CIDP and for multifocal neuropathy. The cost of IVIg for these neuropathies in Australia is approximately 60 million dollars per year. As new indications for IVIg continue to be developed the resource becomes more valuable. We plan to explore the mechanism of action of IVIg with the aim of saving this precious resource and providing significant financial savings to the health service.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2015

Funding Scheme: NHMRC Project Grants

Funding Amount: $452,141.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Neurology And Neuromuscular Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Dendritic cells | Experimental autoimmune neuritis (EAN) | Fc gamma receptors | Immune therapies | Inflammatory neuropathies | Intravenous immunoglobulin (IVIg)

Related Links